Asivatrep | 1005168-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Asivatrep
• 英文别名: (E)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide
• CAS: 1005168-10-4
• 化学式: C₂₁H₂₂F₅N₃O₃S
• 分子量: 491.5
• InChiKey: UKGJZDSUJSPAJL-YPUOHESYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  96.5
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES
  申请人：AMOREPACIFIC CORPORATION

  公开号：US20170342027A1

  公开（公告）日：2017-11-30

  The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O′-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O′-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

  本规范涉及一种手性分离方法，包括以下步骤：将含有胺基与不对称碳原子结合的化合物的立体异构物混合物与手性辅助剂和盐形成辅助剂混合，其中手性辅助剂是O,O′-二酰基酒石酸衍生物，更具体地说是2,3-二苯乙酰酒石酸或O,O′-二对甲苯酰酒石酸，盐形成辅助剂是苯甲酸或藿香磺酸，通过使用该方法可以获得具有高光学纯度的光学异构体。因此，根据本发明的一个方面，在制备具有高光学纯度的光学异构体时，该方法在制药或化妆品领域中可能是有用的。
• METHOD FOR PREPARING (R)-N-[4-(1-AMINO-ETHYL)-2,6-DIFLUORO-PHENYL]-METHANESULFONAMIDE
  申请人：AMOREPACIFIC CORPORATION

  公开号：US20200031766A1

  公开（公告）日：2020-01-30

  Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the re-crystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.

  本说明书公开了一种方法，通过选择Ellman手性辅助剂和光学异构体的重结晶和分离，能够制备具有高光学纯度的N-[4-[(1R)-1-[[(R)-(1,1-二甲基乙基)亚磺酰基]氨基]乙基]-2,6-二氟苯基]-甲磺酰胺（INT028-2）。根据上述方法，在改善实现高光学纯度所必需的低温过程条件的情况下，可以在室温下生产具有优异质量的高纯度N-[4-[(1R)-1-[[(R)-(1,1-二甲基乙基)亚磺酰基]氨基]乙基]-2,6-二氟苯基]-甲磺酰胺，从而可以显着降低由于工艺失效率而导致的修剪。
• NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：KIM Sun-Young

  公开号：US20080312234A1

  公开（公告）日：2008-12-18

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

  本发明涉及一种新型化合物、其异构体或其药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1；VR1；TRPV1）拮抗剂；以及包含该化合物的药物组合物。本发明提供了一种用于预防或治疗疾病的药物组合物，例如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合症、排便紧迫、呼吸道疾病、皮肤、眼睛或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳疾病、心脏疾病等。
• COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS
  申请人：Amorepacific Corporation

  公开号：EP3677264A1

  公开（公告）日：2020-07-08

  The present invention relates to an external skin application composition containing a TRPV1 receptor antagonist and, more specifically, to an external skin application composition for preventing and/or treating atopic dermatitis without side effects such as a body temperature increase and epidermal atrophy.

  本发明涉及一种含有 TRPV1 受体拮抗剂的皮肤外用组合物，更具体地说，涉及一种用于预防和/或治疗特应性皮炎且无体温升高和表皮萎缩等副作用的皮肤外用组合物。
• PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE
  申请人：Amorepacific Corporation

  公开号：EP3666254A2

  公开（公告）日：2020-06-17

  One aspect of the present disclosure is a pharmaceutical composition which includes (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl- 6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

  本公开的一个方面是一种药物组合物，它包括作为第一组分的(R)-N-[1-(3,5-二氟-4-甲磺酰氨基-苯基)-乙基]-3-(2-丙基-6-三氟甲基吡啶-3-基)-丙烯酰胺和作为第二组分的纤维素聚合物，其中本公开的一个方面的组合物具有晶体形成延迟时间长的配方特性。